Skip to main content
SpringerLink
Log in

Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis

  • Research Article
  • Published:
Tumor Biology

Abstract

Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) displayed their roles in prognosis prediction in prostate cancer. The objective of the present study was to conduct a systematic review and meta-analysis of published literature while investigating the correlation between survival outcome and CTCs or DTCs counts in patients with prostate cancer. Relevant literature was searched in Pubmed and Embase. Survival data of included study were extracted. Forrest plots were used to estimate the effect of CTCs/DTCs on the survival of patients. Publication bias was evaluated using Begg’s test. The estimated HRs and 95 % confidence interval for the effect of CTCs/DTCs on overall survival (OS) and biochemical relapse-free survival (bRFS) or disease-free survival (DFS) were 2.43 [2.07, 2.86] (p < 0.00001) and 2.15 [1.69, 2.73] (p < 0.00001), respectively. Subgroup analysis revealed that CTCs were also relevant to poor prognosis (hazard ratio (HR) 2.43 [2.05, 2.89] for OS, HR 2.46 [2.08, 2.90] for bRFS/DFS). A similar result was yielded in DTCs (1.47 [1.21, 1.80] for DFS). CTCs/DTCs could also predict poor OS in metastatic prostate cancer (2.37 [1.99, 2.82], p < 0.00001) and in localized stage (HR 1.84 [1.47, 2.28], p < 0.00001). In addition, CTCs/DTCs detected by different methods, especially by CellSearch system (HR for OS 2.36 [1.95, 2.85] and HR for bRFS/DFS 2.53 [1.66, 3.85]), were relevant to poor prognosis. Available evidence supported the notion of the strong prognostic value of CTCs. CTCs are promising biomarkers that are clinically implemented in the therapeutic decision-making process in patients with prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2:389–96.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Cooner WH, Mosley BR, Rutherford Jr CL, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143:1144–6.

    Google Scholar 

  4. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:1605–12.

    Article  PubMed  Google Scholar 

  5. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. Eau guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.

    Article  PubMed  Google Scholar 

  6. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146–9.

    Google Scholar 

  7. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793–802.

    Article  CAS  PubMed  Google Scholar 

  8. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012;18:5701–10.

    Article  PubMed  Google Scholar 

  9. ᅟCohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26:3213–3221.

    Google Scholar 

  10. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:1556–63.

    Article  Google Scholar 

  11. Olmos D, Arkenau H, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol. 2009;20:27–33.

    Article  CAS  PubMed  Google Scholar 

  12. Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996;347:649–53.

    Article  CAS  PubMed  Google Scholar 

  13. Pierga J-Y, Bidard F-C, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:7004–10.

    Article  CAS  Google Scholar 

  14. Rack BK, Schindlbeck C, Schneeweiss A, Hilfrich J, Lorenz R, Beckmann MW, Pantel K, Lichtenegger W, Sommer HL, Janni WJ. Prognostic relevance of circulating tumor cells (CTCS) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: the german success-trial. 2008.

  15. Ghossein R, Rosai J, Scher H, Seiden M. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic. Urology. 1997;4295:100–5.

    Article  Google Scholar 

  16. Goodman OB, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomark Prev. 2009;18:1904–13.

    Article  CAS  Google Scholar 

  17. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232–7.

    Article  PubMed  Google Scholar 

  18. Hara N, Kasahara T, Kawasaki T. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res. 2002;8:1794–9.

    CAS  PubMed  Google Scholar 

  19. Joung JAEY, Cho KSU, Kim JEUN, Seo HOK, Chung J, Park WSEO, et al. Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. J Surg Oncol. 2010;101:145–8.

    PubMed  Google Scholar 

  20. Lembessis P, Msaouel P. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts. Clin Chem Lab Med. 2007;45:1488–94.

    Article  CAS  PubMed  Google Scholar 

  21. Moreno J, Miller M, Gross S, Allard W. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005;65:713–8.

    Article  PubMed  Google Scholar 

  22. Okegawa T, Nutahara K, Higashihara E. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic. J Urol. 2008;180:1342–7.

    Article  PubMed  Google Scholar 

  23. Okegawa T, Nutahara K, Higashihara E. Original article: clinical investigation association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory. Int J Urol. 2010;17:466–75.

    Article  CAS  PubMed  Google Scholar 

  24. Okegawa T, Nutahara K, Higashihara E. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol. 2009;181:1091–7.

    Article  PubMed  Google Scholar 

  25. Olsson CA, Vries GMDE, Raffo AJ, Benson MC, Otoole K, Cao Y, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol. 1996;155:1557–62.

    Article  CAS  PubMed  Google Scholar 

  26. Scher HI, Jia X, Bono JSD, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer : a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10:233–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Strijbos MH, Gratama JW, Schmitz PIM, Rao C, Onstenk W, Doyle GV, et al. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur J Cancer. 2010;46:2027–35.

    Article  CAS  PubMed  Google Scholar 

  28. Thomas C, Wiesner C, Melchior SW, Schmidt F, Gillitzer R, Thüroff JW, et al. Urokinase-plasminogen-activator receptor expression in desseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. Int Br J Urol. 2008;104:29–34.

    Article  Google Scholar 

  29. Weckermann D, Polzer B, Ragg T, Blana A, Bertz S, Harzmann R, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009;27:1549–56.

    Article  PubMed  Google Scholar 

  30. Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kreß V, et al. Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol. 2013;139:755–63.

    Article  PubMed  Google Scholar 

  31. Resel Folkersma L, San José Manso L, Galante Romo I, Moreno Sierra J, Olivier Gómez C. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology. 2012;80:1328–32.

    Article  PubMed  Google Scholar 

  32. Wood Jr DP, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15:3451–7.

    Google Scholar 

  33. Berg A, Berner A, Lilleby W, Bruland ØS, Foss SD. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer. 2007;120:1603–9.

    Article  CAS  PubMed  Google Scholar 

  34. Gewanter R, Katz A, Olsson C. RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy. Urology. 2003;4295:967–71.

    Article  Google Scholar 

  35. Mejean A, Vona G, Naplas B. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol. 2000;163:2022–9.

    Article  CAS  PubMed  Google Scholar 

  36. Oefelein M, Ignatoff J. Clinical and molecular followup after radical retropubic prostatectomy. J Urol. 1999;162:307–10.

    Article  CAS  PubMed  Google Scholar 

  37. Shariat S, Gottenger E, Nguyen C. Reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002;62:5974–9.

    CAS  PubMed  Google Scholar 

  38. Tierney JF, Stewart L, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Bianco Jr FJ, Powell IJ, Cher ML, Wood Jr DP. Presence of circulating prostate cancer cells in African American males adversely affects survival. Urologic Oncology: Seminars and Original Investigations, Elsevier, 2002, 7, pp 147–152.

  40. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary Clinical Trials. 2007;28:105–14.

    Article  PubMed  Google Scholar 

  41. Easterbrook PJ, Gopalan R, Berlin JA, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72.

    Article  CAS  PubMed  Google Scholar 

  42. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009;15:677–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:2023–9.

    Article  CAS  PubMed  Google Scholar 

  44. Doyen J, Alix-Panabières C, Hofman P, Parks SK, Chamorey E, Naman H, et al. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Critical Rev Oncol/Hematol. 2012;81:241–56.

    Article  Google Scholar 

  45. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Groot Koerkamp B, Rahbari NN, Buchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Annals Surg Oncol. 2013;20:2156–65.

    Article  Google Scholar 

  47. Ma X-L, Xiao Z-L, Liu L, Liu X-X, Nie W, Li P, et al. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev. 2012;13:1137–44.

    Article  PubMed  Google Scholar 

  48. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: When is “statistically significant” clinically useful? Prognostic variables in node-negative and node-positive breast cancer, Breast Cancer Res Tr. Kluwer Academic Publishers, Netherlands, 1998, 395–409.

  49. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329–40.

    Article  CAS  PubMed  Google Scholar 

  50. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer cell. 2013;23:573–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Hou J-M, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30:525–32.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China

    Xuelei Ma, Fengtian Wang, Jing Zhang & Lei Liu

  2. West China Medical School, West China Hospital, Sichuan University, Chengdu, 610041, China

    Zhilan Xiao, Xiaojun Li & Rubai Zhou

  3. Urological Surgery Department, West China Hospital, Sichuan University, Chengdu, China

    Junbo Wang

  4. Medical Oncology, West China Hospital, 37 Guoxuexiang Street, Chengdu, 610000, China

    Lei Liu

Authors
  1. Xuelei Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhilan Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaojun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fengtian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rubai Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Junbo Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lei Liu.

Additional information

Xuelei Ma, Zhilan Xiao, and Xiaojun Li contributed equally to the study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ma, X., Xiao, Z., Li, X. et al. Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. Tumor Biol. 35, 5551–5560 (2014). https://doi.org/10.1007/s13277-014-1731-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1731-5

Keywords

Search

Navigation